AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2022
Apr 20, 2022
33148_dirs_2022-04-20_5e4b02bc-de3b-42f3-9844-d6cdba3f2808.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2022-04-18
Reporting Person: Militello John (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-18 | Stock Option (Right to Buy) | $13.12 | A | 28910 | Acquired | 2032-04-17 | Common Stock (28910) | Direct |
| 2022-04-18 | Restricted Stock Units | $ | A | 19054 | Acquired | Common Stock (19054) | Direct |
Footnotes
F1: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: One-third (1/3) of such restricted stock units will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.